LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
Date:
Wednesday, October 29, 2025 | |
Time: | 5:00 p.m. U.S. EDT |
Webcast: |
A replay of the conference call will be available on the investor relations website.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Investor Contact: | Media Contact: | |
Garen Sarafian | Katie Savastano | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
(877) 281-6642 (toll-free) | (908) 541-3785 |
| Last Trade: | US$6.82 |
| Daily Volume: | 1,291,252 |
| Market Cap: | US$2.530B |
December 01, 2025 November 05, 2025 October 29, 2025 September 11, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
